GLP-1 dose schedules: how Ozempic, Wegovy, Mounjaro and Zepbound step up

Photo: Vitaly Gariev / Unsplash
Every weekly GLP-1 starts at a low dose and goes up in steps of at least 4 weeks. The labels say why: the escalation is there to reduce the risk of stomach and gut side effects. Here are the schedules as the US labels print them, and what they leave to your prescriber.
Why the dose goes up in steps
Each label tells prescribers to follow the dose escalation "to reduce the risk of gastrointestinal adverse reactions": nausea, vomiting, diarrhea and the like. The same labels report that most of those reactions happened during the escalation, and for Mounjaro and Zepbound that they decreased over time. More on that in side effects after a GLP-1 shot.
All four at a glance
| Medicine | Start | Steps | Highest dose in the label |
|---|---|---|---|
| Wegovy injection | 0.25 mg, weeks 1–4 | 0.5 mg weeks 5–8, 1 mg weeks 9–12, 1.7 mg weeks 13–16, then maintenance | 7.2 mg (adults, weight reduction, see below) |
| Ozempic | 0.25 mg for 4 weeks | 0.5 mg; then 1 mg and 2 mg, each after at least 4 weeks, if needed for blood sugar control | 2 mg |
| Zepbound | 2.5 mg for 4 weeks | 5 mg; then up in 2.5 mg steps, each after at least 4 weeks | 15 mg |
| Mounjaro | 2.5 mg | up in 2.5 mg steps, each after at least 4 weeks, if needed for blood sugar control | 15 mg (adults) |
All once weekly, from each medicine's US prescribing information (section 2).
Wegovy
Wegovy is the only one of the four with a fixed week-by-week table in its label:
- Weeks 1–4: 0.25 mg. Weeks 5–8: 0.5 mg. Weeks 9–12: 1 mg. Weeks 13–16: 1.7 mg.
- Week 17 on: the maintenance dose. For weight reduction in adults, that is 1.7 mg or 2.4 mg, with 2.4 mg recommended.
- For adults who tolerate 2.4 mg for at least 4 weeks and need more weight reduction, the label allows up to 7.2 mg once weekly.
- If a dose isn't tolerated during the escalation, the label says to consider delaying the next step by 4 weeks.
The daily Wegovy tablets have their own schedule: 1.5 mg on days 1–30, 4 mg on days 31–60, 9 mg on days 61–90, and 25 mg from day 91.
Ozempic
Ozempic is a type 2 diabetes medicine, and its steps after the start depend on blood sugar control:
- 0.25 mg once weekly for 4 weeks, then 0.5 mg.
- If more blood sugar control is needed after at least 4 weeks on 0.5 mg, the dose may go up to 1 mg; after at least 4 weeks on 1 mg, to 2 mg.
- 2 mg is the maximum. For people with type 2 diabetes and chronic kidney disease, the label's maintenance dose is 1 mg.

Zepbound and Mounjaro
Both contain tirzepatide and move in 2.5 mg steps.
- Zepbound starts at 2.5 mg for 4 weeks. The label is explicit that 2.5 mg is for starting treatment and is not a maintenance dose. After 4 weeks it goes to 5 mg, and from there it may go up by 2.5 mg after at least 4 weeks on the current dose.
- Zepbound's maintenance dose is 5, 10 or 15 mg for weight reduction, and 10 or 15 mg for obstructive sleep apnea. If a maintenance dose isn't tolerated, the label says to consider a lower one.
- Mounjaro starts at 2.5 mg and, if more blood sugar control is needed, goes up by 2.5 mg after at least 4 weeks on the current dose, to a maximum of 15 mg in adults.
"At least 4 weeks" is a minimum
Outside Wegovy's fixed table, the labels say at least 4 weeks per step, and they leave the decision to step up, stay, or go back to your prescriber: based on how you're doing and how you tolerate the dose. A schedule that looks slower than the chart is not a sign that something is wrong.
Don't change your dose on your own. Use the dose your prescriber gave you, and ask them or your pharmacist when you're unsure.
After a step up
Because most stomach and gut side effects were reported during the escalation, the weeks right after a step up are the ones worth watching. A useful record is simple: the date of each dose change, and how you felt on each day of the weeks before and after it. Then you can see whether a new dose changed anything, and for how long, and tell your prescriber in facts rather than impressions.

This page is general information from the sources below, not medical advice. Your dose and when it changes are decided by your prescriber; follow them and the leaflet that comes with your medicine.
- Wegovy (semaglutide) injection and tablets: US Prescribing Information, Novo Nordisk, revised 06/2026 (sections 2.2 and 2.3, Tables 1 and 2), checked 20 November 2026.
- Ozempic (semaglutide) injection: US Prescribing Information, Novo Nordisk, revised 05/2026 (section 2.2), checked 20 November 2026.
- Zepbound (tirzepatide) injection: US Prescribing Information, Eli Lilly, revised 11/2026 (sections 2.1 and 2.2), checked 20 November 2026.
- Mounjaro (tirzepatide) injection: US Prescribing Information, Eli Lilly, revised 11/2026 (section 2.1), checked 20 November 2026.